Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Takeda Pharmaceutical ADR Rep 0.5 Ord Shs TAK

Healthcare
Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer)... see more

Recent & Breaking News (NYSE:TAK)

Takeda Demonstrates Its Long-Standing Commitment to Advancing Treatments for Rare Bleeding Disorders with Studies Highlighting Real-World Evidence and Investigational Gene Therapy at ASH 2019

Business Wire December 9, 2019

Takeda Presents 18-Month Data from Pivotal Phase 3 Trial of Dengue Vaccine Candidate at the American Society of Tropical Medicine and Hygiene (ASTMH) 68th Annual Meeting

Business Wire November 23, 2019

Takeda Presents Long-Term Data in ALK+ NSCLC Showing ALUNBRIG® (brigatinib) Continues to Demonstrate Superiority in the First-Line After Two Years of Follow-Up

Business Wire November 22, 2019

Takeda Announces 12 New Molecular Entities with the Potential for 14 Launches in the Next Five Years at 2019 R&D Day

Business Wire November 14, 2019

New Analyses from the Phase 3 HELP Study(TM) Open-Label Extension in Hereditary Angioedema Evaluate Efficacy and Safety of TAKHZYRO® (lanadelumab-flyo) Injection During Extended Study Treatment Period

Business Wire November 8, 2019

Takeda Unveils New Dengue Vaccine Manufacturing Plant in Germany

Business Wire November 5, 2019

Takeda and MD Anderson Announce Collaboration to Accelerate the Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell Therapy Platform

Business Wire November 5, 2019

Takeda Continues Strategic Divestitures With Sale of Select OTC and Non-Core Assets to STADA for $660 Million USD

Business Wire November 5, 2019

Takeda Reports Solid Second Quarter FY2019 Results and Raises Profit Guidance for the Full Year

Business Wire October 31, 2019

First-Ever U.S. Pivotal Phase 3 Clinical Study in Eosinophilic Esophagitis (EoE) Completes: Takeda's Investigational Therapy Meets Co-Primary & Key Secondary Efficacy Endpoints

PR Newswire October 28, 2019

Takeda Acquires License for First-In-Class Celiac Disease Therapy from COUR Pharmaceuticals Following Positive Phase 2a Proof-of-Concept Study

Business Wire October 22, 2019

Retrospective Real-World Comparative Analysis Highlights Safety of Vedolizumab and Anti-TNF? Therapies in Biologic-Naïve Patients with Ulcerative Colitis or Crohn's Disease

Business Wire October 21, 2019

Takeda Agrees to Divest Select OTC and Non-core Assets to Acino for Over $200 Million USD

Business Wire October 15, 2019

New Data Presented at World Sleep Congress Demonstrate Early Signs of Efficacy for TAK-925, a Selective Orexin Type-2 Receptor (OX2R) Agonist, in Patients with Narcolepsy Type 1

Business Wire September 25, 2019

First Head-to-Head Biologic Study in Ulcerative Colitis Published in The New England Journal of Medicine Highlights Benefit of Vedolizumab vs. Adalimumab

Business Wire September 25, 2019

New England Journal of Medicine Publishes Results of a Phase 2 Trial Evaluating Takeda's TAK-620 (Maribavir) as a Potential Treatment of Cytomegalovirus (CMV) Infection

Business Wire September 24, 2019

Takeda Recognized in the 2019 Dow Jones Sustainability World Index

Business Wire September 19, 2019

NICE Recommends Takhzyro® (Lanadelumab) for the Treatment of People Living With Rare Debilitating Genetic Disorder

PR Newswire September 18, 2019

Takeda Issues US Recall of NATPARA® (parathyroid hormone) for Injection Due to the Potential for Rubber Particulate

Canada NewsWire September 5, 2019

Takeda Announces FY2019 Key Performance Indicators Aligned with Shareholder Value Creation and Focused on Successful Integration

Business Wire July 31, 2019